Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina S Oxlund

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|April 28, 2023
Birgit K Skovbjerg, Ole Kl Helgestad, Christina S Oxlund, et al.
Journal of Hypertension|October 11, 2013
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trialChristina S Oxlund, Jan E Henriksen, Lise Tarnow, et al.
Journal of Hypertension|May 9, 2014
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitroKristian B Buhl, Christina S Oxlund, Ulla G Friis, et al.
Journal of the American Society of Hypertension : JASH|December 11, 2014
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertensionChristina S Oxlund, Kristian B Buhl, Ib A Jacobsen, et al.
Acta Physiologica (Oxford, England)|September 22, 2018
The acute blood pressure-lowering effect of amiloride is independent of endothelial ENaC and eNOS in humans and miceRikke Ydegaard, Henrik Andersen, Christina S Oxlund, et al.
American Journal of Physiology. Renal Physiology|May 23, 2024
Amiloride lowers plasma TNF and interleukin-6 but not interleukin-17A in patients with hypertension and type 2 diabetesSai Sindhu Thangaraj, Christina S Oxlund, Henrik Andersen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|April 28, 2023
Birgit K Skovbjerg, Ole Kl Helgestad, Christina S Oxlund, et al.
Journal of Hypertension|October 11, 2013
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trialChristina S Oxlund, Jan E Henriksen, Lise Tarnow, et al.
Journal of Hypertension|May 9, 2014
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitroKristian B Buhl, Christina S Oxlund, Ulla G Friis, et al.
Journal of the American Society of Hypertension : JASH|December 11, 2014
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertensionChristina S Oxlund, Kristian B Buhl, Ib A Jacobsen, et al.
Acta Physiologica (Oxford, England)|September 22, 2018
The acute blood pressure-lowering effect of amiloride is independent of endothelial ENaC and eNOS in humans and miceRikke Ydegaard, Henrik Andersen, Christina S Oxlund, et al.
American Journal of Physiology. Renal Physiology|May 23, 2024
Amiloride lowers plasma TNF and interleukin-6 but not interleukin-17A in patients with hypertension and type 2 diabetesSai Sindhu Thangaraj, Christina S Oxlund, Henrik Andersen, et al.
Pageof 1